Immune checkpoint inhibitors affect the potency of chemotherapeutic drugs in head and neck squamous cell carcinoma lines

Cancer treatment often relies on a two-pronged approach: drugs that directly attack rapidly dividing cells, and therapies that wake up the body's own immune system to hunt down the disease. For years, doctors have assumed these two methods work in separate lanes. The immune drugs, known as checkpoint inhibitors, were thought to function solely by removing the brakes on immune cells, allowing them to recognize and destroy tumors. Meanwhile, traditional chemotherapy was seen as a blunt instrument, damaging the genetic machinery of cancer cells regardless of the immune system's presence. However, a growing body of evidence suggests that these treatments might be talking to each other in ways scientists did not anticipate, potentially altering how cancer cells respond to chemical attacks even before the immune system gets involved.

Head and neck cancers, which affect the mouth, throat, and voice box, present a unique puzzle because they are not all the same. Some are driven by a virus called human papillomavirus, or HPV, while others are caused by lifestyle factors like smoking and drinking. These two types of cancer behave differently at a molecular level. The virus-driven cancers often have a specific protein, TP53, that functions normally but is temporarily silenced by the virus. In contrast, non-viral cancers frequently carry broken or mutated versions of this same protein, which can actually help the tumor grow and resist treatment. Understanding how these biological differences interact with modern therapies is crucial for improving patient outcomes, especially since the combination of immune drugs and chemotherapy is now a standard treatment for advanced cases.

Researchers at the University of Tartu in Estonia set out to test a specific hypothesis: do immune checkpoint inhibitors change how cancer cells react to chemotherapy, even if the immune system is completely absent from the equation? To find the answer, they worked in a controlled laboratory environment, growing human cancer cells in dishes. They used two distinct types of head and neck cancer cells: one that was HPV-negative and carried a mutated TP53 protein, and another that was HPV-positive with a normal, working TP53 protein. The team treated these cells with standard chemotherapy drugs—such as cisplatin, which damages DNA, and paclitaxel, which stops cells from dividing—both alone and in combination with two widely used immune drugs, pembrolizumab and nivolumab. Crucially, because these experiments happened in a dish without any immune cells, any changes in the cancer cells' behavior had to be caused by the immune drugs acting directly on the cancer cells themselves.

The results revealed that the immune drugs did indeed change the potency of the chemotherapy, but the effect depended entirely on which drug was used and which type of cancer cell was being treated. When the researchers mixed the immune drug nivolumab with paclitaxel, the cancer cells became more sensitive to the chemotherapy, meaning the drug worked better than it did on its own. This was particularly true for the HPV-negative cells with the mutated protein. In these cells, the combination led to a significant drop in the levels of the mutated protein and markers of cell division, suggesting the cancer cells were struggling to survive and divide. However, the story was different for another common chemotherapy drug, 5-fluorouracil. When the immune drugs were added to this treatment, they actually made the chemotherapy less effective. The cancer cells survived better than expected, showing higher levels of the mutated protein and getting stuck in a state of stress without dying.

To understand what was happening inside the cells, the team looked at the physical structure of the cancer colonies. When they grew the cells in three-dimensional balls, known as spheroids, to mimic how tumors grow in the body, they saw that the combination of nivolumab and paclitaxel caused the cancer balls to fall apart more easily than paclitaxel alone. The cells lost their grip on one another, a sign that the drug combination was disrupting the structural integrity of the tumor. In contrast, the immune drugs did not change how the cells responded to 5-fluorouracil in these three-dimensional models, reinforcing the idea that the immune drugs were interfering with specific cellular pathways rather than causing a general change in how the cells handled all drugs.

The study also highlighted that not all immune drugs are identical in their effects. While nivolumab showed a broad ability to boost the power of certain chemotherapy drugs, pembrolizumab had a more limited and sometimes opposite effect, reducing the effectiveness of paclitaxel in one cell line and 5-fluorouracil in both. This suggests that the specific shape and behavior of the immune drug molecule matter, as they may trigger different internal signals within the cancer cell. The researchers found that these interactions were linked to the status of the TP53 protein and the presence of the HPV virus. The cells with the broken protein responded differently than those with the normal protein, indicating that the internal genetic makeup of the tumor dictates how it will react when an immune drug is present.

These findings challenge the simple view that immune drugs only work by recruiting the body's defenders. Instead, the study suggests that these drugs can directly alter the stress responses and survival mechanisms of cancer cells, making them more or less vulnerable to chemical attacks depending on the specific drug combination and the tumor's biology. While the changes in drug potency were measurable and statistically significant, the researchers note that these experiments took place in a dish without the complex environment of a living human body. The immune system, blood flow, and other tissues could modify these effects in a patient. Nevertheless, the work provides a clear warning and a new direction for medical science: the choice of chemotherapy and immune therapy cannot be made in isolation. Doctors must consider the specific genetic profile of the tumor, including whether it is driven by a virus and what state its key proteins are in, to avoid accidentally weakening a treatment or to maximize its strength. The path forward for treating head and neck cancer may require a more precise matching of drugs to the unique biological signature of each patient's tumor.